{"product_id":"harvard-psychopharmacology","title":"Harvard Psychopharmacology: A Master Class 2023","description":"\u003ch3\u003eHarvard Psychopharmacology: A Master Class 2023\u003c\/h3\u003e\u003cbr\u003eWe are pleased to offer our 13th annual two-day course uniquely designed for practicing clinicians, clinical researchers and trainees in psychiatry. Presentations will focus on typical psychiatric patients with emphasis on those who are difficult to treat or are treatment resistant. Newer treatments and developing treatment strategies will be discussed including the use of genetic tests, blood level measurements and drug combinations. There will be considerable opportunity for interaction with the presenters.\u003cbr\u003e\u003ch4\u003eHarvard Psychopharmacology: A Master Class 2023\u003c\/h4\u003e\n\u003ch4\u003eApril 28, 2023 – April 29, 2023\u003c\/h4\u003e\n\u003ch4\u003eVideos +PDF\u003c\/h4\u003e\n\u003ch4\u003e2023 Course Overview\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eThis conference will focus on the following topics: An updated review of neurobiology and brain function taking the attendee through neurotransmission sequence from the central role of neurotransmitter circuits, transmitters and receptors, synaptic function and gene transcription. Interaction between genes and the environment. Drug treatment of schizophrenia and bipolar disorder will be presented with a focus on prodromal symptoms and first episode patients, as well as long-term maintenance and treatment resistant patients.\u003c\/li\u003e\n\u003cli\u003eNew antipsychotic medications and treatment augmentation will be reviewed along with potential new uses for mood stabilizers. Neurobiological mechanisms of depression with a discussion of both the genetic and epigenetic contribution as well as the role of inflammation will be highlighted. Modern use of antidepressants will be based on the latest clinical findings. Special consideration will be given to ketamine, ECT, TMS, psychedelics and augmentation strategies for treatment resistant depression and bipolar depression. Diagnosis and treatment of of Anxiety, Borderline Personality Disorder, OCD and eating disorder patients will be presented, along with a discussion of the risks and benefits of benzodiazepines. The etiology and treatment of PTSD will be discussed. Special consideration will be given to use of blood levels and dosing and innovative combinations in the treatment of resistant psychiatric disorders. The importance of the evaluation and psychopharmacological treatment of women’s mental health issues will be addressed with particular emphasis on PMS, perinatal and postpartum disorders. The course will also include a review of the neurobiology and treatment of sleep disorders in psychiatry as well as a lecture on the neurobiology and treatment of alcohol, cannabis and other substance abuse disorders. Latest advances in geriatric psychopharmacology will be reviewed.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAnxiety and anxiety-spectrum disorders as well as their pharmacological treatment will be presented, including panic disorder, social anxiety disorder and generalized anxiety disorder. New concepts and treatments of obsessive compulsive disorder will be reviewed as well as the pharmacological treatment of borderline personality disorder. The importance of the evaluation and psychopharmacological treatment of women’s mental health issues will be addressed with particular emphasis on PMS, perinatal and postpartum disorders and treatment resistant PTSD. The course will also include a review of the role of psychopharmacology in the treatment of sleep disorders. Advances in the neurobiology and treatment of alcohol and substance abuse disorders will also be highlighted. The latest advances in child, adolescent and geriatric psychopharmacology will be emphasized. Throughout the course the establishment and importance of the therapeutic alliance when prescribing all psychotropic medications will be underscored, as will the potential hazards\/benefits of polypharmacy drug interactions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eWho Should Attend\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003ePsychiatrists\u003c\/li\u003e\n\u003cli\u003eResearchers in Psychopharmacology and Neuroscience\u003c\/li\u003e\n\u003cli\u003eSubstance Abuse and Mental Health Clinicians and Researchers\u003c\/li\u003e\n\u003cli\u003ePharmacists\u003c\/li\u003e\n\u003cli\u003eNurses\u003c\/li\u003e\n\u003cli\u003eNurse Practitioners\u003c\/li\u003e\n\u003cli\u003ePrimary Care Physicians\u003c\/li\u003e\n\u003cli\u003eSpecialty Physicians\u003c\/li\u003e\n\u003cli\u003ePsychologists\u003c\/li\u003e\n\u003cli\u003ePhysician Assistants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eLearning Objectives\u003c\/h4\u003e\u003cbr\u003eUpon completion of this activity, participants will be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eEvaluate the effects of neurotransmitters and genes on psychotropic drug treatment.\u003cbr\u003eStudy the interface between neurology and psychiatry.\u003cbr\u003eDescribe the pharmacologic treatment of schizophrenia with particular reference to the prodromal period and first episode.\u003cbr\u003eSummarize the interface between medicine and psychiatric disorders with an emphasis on cardiovascular disease and cancer.\u003cbr\u003eOutline the emerging theories and treatments of bipolar disorder, depression, treatment resistant depression, bipolar depression, stress and anxiety disorder.\u003cbr\u003eIdentify the benefits and risks of ketamine.\u003cbr\u003eDiscuss the role of psychotropic medications in women’s mental health with an emphasis on PMS, pregnancy, nursing and the postpartum period.\u003cbr\u003eIdentify emerging treatments for PTSD.\u003cbr\u003eExplain the role of psychopharmacology in the treatment of substance use disorders with particular emphasis on alcohol, opiates and cannabis.\u003cbr\u003eGive examples of the latest advances and problems associated with treatment approaches in the geriatric populations.\u003cbr\u003eDiscuss standard psychopharmacologic treatments that have now been proven to be ineffective.\u003cbr\u003eDiscuss the application of digital phenotype tools in the psychopharmacologic management of psychiatric disorders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e2023 Agenda\u003c\/h3\u003e\n\u003ch5\u003eInformation for the 2024 course is not yet available.\u003c\/h5\u003e\n\u003ch5\u003eAll agenda sessions are in Eastern Time.\u003c\/h5\u003e\n\u003ch3 style=\"text-align: center;\"\u003eFRIDAY, APRIL 28, 2023\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRegistration\u003c\/li\u003e\n\u003cli\u003eWelcome Remarks\u003cbr\u003eCarl Salzman, MD\u003c\/li\u003e\n\u003cli\u003eNeurobiology for the Practicing Clinician: Understanding Brain Function and its Relevance to Drug Treatment in Psychiatry\u003cbr\u003eMatcheri Keshavan, MD\u003c\/li\u003e\n\u003cli\u003eMechanisms of Action and the Development of New Antidepressants\u003cbr\u003eAlan Schatzberg, MD\u003c\/li\u003e\n\u003cli\u003ePsychopharmacology of Childhood and Adolescent Depression\u003cbr\u003eKaren Dineen Wagner, MD, PhD\u003c\/li\u003e\n\u003cli\u003eCurrent Treatment for Schizophrenia: Prodrome First Episode, Relapse and New Treatment Possibilities\u003cbr\u003eMatcheri Keshavan, MD\u003c\/li\u003e\n\u003cli\u003eWhat You Should Really Know About the Treatment of Mania and Bipolar Depression\u003cbr\u003eRoscoe Brady, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion\u003cbr\u003eRoscoe Brady, MD, Matcheri Keshavan, MD, Carl Salzman, MD, Alan Schatzberg, MD, Karen Dineen Wagner, MD, PhD\u003c\/li\u003e\n\u003cli\u003eBrain Inflammation in Neuropsychiatry\u003cbr\u003ePaulo Lizano, MD\u003c\/li\u003e\n\u003cli\u003eNeural Circuitry Based Treatments in Psychiatry\u003cbr\u003eRoscoe Brady, MD\u003c\/li\u003e\n\u003cli\u003eDecision Making in the Treatment of Resistant Psychiatric Disorders: From Blood Levels to Dosing to Treatment Combinations\u003cbr\u003eStephen Stahl, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion\u003cbr\u003eRoscoe Brady, MD, Paulo Lizano, MD, Stephen Stahl, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"text-align: center;\"\u003eSATURDAY, APRIL 29, 2023\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRational Use of Benzodiazepines in Anxiety Spectrum Disorders\u003cbr\u003eCarl Salzman, MD\u003c\/li\u003e\n\u003cli\u003eSleep in Psychiatric Disorders:\u003cbr\u003eRobert Stickgold, PhD, Anthony (Tony) Cunningham, PhD\u003c\/li\u003e\n\u003cli\u003eDigital Phenotyping in Psychiatry and Psychopharmacology\u003cbr\u003eJohn Torous, MD\u003c\/li\u003e\n\u003cli\u003eDifficult to Treatment Patients: Borderline Personality Disorder, OCD, and Eating Disorders\u003cbr\u003eCarl Salzman, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion\u003cbr\u003eCarl Salzman, MD, John Torous, MD, Robert Stickgold, PhD, Anthony (Tony) Cunningham, PhD\u003c\/li\u003e\n\u003cli\u003eEffective Treatment of Substance Use Disorders\u003cbr\u003eKevin Hill, MD\u003c\/li\u003e\n\u003cli\u003eThe Psychopharmacology of the Reproductive Life Cycle: Premenstrual, Pregnancy, Lactation, and Menopause\u003cbr\u003eCatherine Lager, MD, Marcela Almeida, MD\u003c\/li\u003e\n\u003cli\u003eOlder People Are Not All the Same: Differing Approaches for Younger Old and Older Old\u003cbr\u003eCarl Salzman, MD\u003c\/li\u003e\n\u003cli\u003ePanel Discussion\u003cbr\u003eCarl Salzman, MD, Catherine Lager, MD, Marcela Almeida,MD, Kevin Hill, MD\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954287382626,"sku":"MED-AMB00303","price":2.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Harvard-Psychopharmacology-A-Master-Class-2023-1.jpg?v=1779370062","url":"https:\/\/meducourse.com\/products\/harvard-psychopharmacology","provider":"Meducourse","version":"1.0","type":"link"}